Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
Dominika Hromadová, Dirk Elewaut, Robert D. Inman, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 19

Showing 19 citing articles:

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279
Silvana Leit, Jeremy R. Greenwood, Samantha Carriero, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10473-10496
Closed Access | Times Cited: 26
TYK2: an emerging therapeutic target in rheumatic disease
Eric F. Morand, Joseph F. Merola, Yoshiya Tanaka, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 232-240
Closed Access | Times Cited: 14
JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance
S. P. Raychaudhuri, Ruchi J. Shah, Sneha Banerjee, et al.
Current Rheumatology Reports (2024) Vol. 26, Iss. 6, pp. 204-213
Open Access | Times Cited: 4
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions
Anzhelika Karjalainen, Agnieszka Witalisz‐Siepracka, Michaela Prchal‐Murphy, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
Éric Toussirot
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 270-270
Open Access | Times Cited: 17
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors
Kuojun Zhang, Ke Ye, He Tang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4378-4416
Closed Access | Times Cited: 10
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease
Ole Haagen Nielsen, Theresa Louise Boye, Deepavali Chakravarti, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 5, pp. 424-436
Closed Access | Times Cited: 14
Investigation on the mechanism of 2,3,4′,5-Tetrahydroxystilbene 2-o-D-glucoside in the treatment of inflammation based on network pharmacology
Ling Sun, Bixu Wang, Tong Sun, et al.
Computers in Biology and Medicine (2022) Vol. 145, pp. 105448-105448
Closed Access | Times Cited: 13
The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease
Marcus Kenyon, Sinead Maguire, Anna Rueda Pujol, et al.
Rheumatology International (2022) Vol. 42, Iss. 12, pp. 2085-2095
Open Access | Times Cited: 12
Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis
Silvana Leit, Jeremy R. Greenwood, Sayan Mondal, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 73, pp. 128891-128891
Closed Access | Times Cited: 11
Fine mapping with epigenetic information and 3D structure
Gisela Orozco
Seminars in Immunopathology (2022) Vol. 44, Iss. 1, pp. 115-125
Open Access | Times Cited: 10
The role of γδ T cells in the immunopathogenesis of inflammatory diseases: from basic biology to therapeutic targeting
Brian Bernal‐Alferes, Rafael Gómez-Mosqueira, Graciela Teresa Ortega-Tapia, et al.
Journal of Leukocyte Biology (2023) Vol. 114, Iss. 6, pp. 557-570
Closed Access | Times Cited: 6
Identifying pathogenic variants related to systemic lupus erythematosus by integrating genomic databases and a bioinformatic approach
Ratih Dewi Yudhani, Dyonisa Nasirochmi Pakha, Suyatmi Suyatmi, et al.
Genomics & Informatics (2023) Vol. 21, Iss. 3, pp. e37-e37
Open Access | Times Cited: 4
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity
Fatemeh Navid, Liye Chen, Paul Bowness, et al.
Nature Reviews Rheumatology (2024)
Closed Access | Times Cited: 1
Novel therapies in axial spondyloarthritis
Mohamad Bittar, Philip J. Mease
Best Practice & Research Clinical Rheumatology (2022) Vol. 36, Iss. 4, pp. 101811-101811
Closed Access | Times Cited: 3
Concise synthesis of pyridopyridazines
Xiaoyan Zheng, Congyu Ke, Sichang Wang, et al.
Tetrahedron Letters (2024) Vol. 149, pp. 155263-155263
Closed Access
Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials
Rouhin Sen, Liron Caplan
Current Opinion in Pharmacology (2022) Vol. 67, pp. 102307-102307
Closed Access | Times Cited: 2
The Sesquiterpene, Selin-11-en-4α-ol, from Artemisia vulgaris Inhibits Lipopolysaccharide-Induced Inflammatory Responses in RAW264.7 Cells via MAPK and NF-κB Signaling Pathways
Ning Wei, Wanwen Dong, Tao Liu, et al.
Natural Product Communications (2023) Vol. 18, Iss. 11
Open Access
Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA)
Sho Fukui, Satoshi Kawaai, Haruki Sawada, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 2, pp. 141-153
Closed Access
Page 1

Scroll to top